Clinical Research




The Center for Genetic Immune Diseases (CGID) specializes in the diagnosis and treatment of genetic primary immune deficiency (PID) and immune regulatory disorders (PIRD), also known as inborn errors of immunity.  In the Center for Genetic Immune Diseases Clinic (CGID-Clinic), immunologists, hematologists, stem cell transplant doctors, infectious disease experts and specialized nurses see patients with often undiagnosed diseases that can present with a variety of symptoms including failure to thrive, autoimmunity, autoinflammation and predisposition to infection. Insights into the genetic origin and underlying molecular defect of a disease enable the care team to decide on the best available treatment option. Treatment options for PIDs and PIRDs include targeted therapies, hematopoietic stem cell transplantation and sometimes gene- and cell therapies. Treatment choices are personalized and differ from patient to patient.  
Targeted Therapies: Autoimmune and autoinflammatory conditions have historically been treated with medication that suppressed the immune system in its entirety, often at the cost of aggravating the immunodeficiency component of the disease. Targeted therapies are drugs that address the underlying disease mechanism more specifically. Often, targeted therapies are “repurposed” drugs that have been FDA-approved for other conditions.
Stem Cell Transplantation: For some patients with severe disease, a hematopoietic stem cell transplantation which replaces the defective immune system, might be considered.
Advanced Gene- and Cell Therapies: For a small number of selected diseases, advanced gene- and cell therapies might be available.
Our interdisciplinary team is devoted to delivering cutting-edge, personalized and compassionate care at Stanford Children’s Health. Our clinic is supported by a generous gift from a philanthropic donor.